Evidence map›Paper›PMID 40627081›Full record

ArticleJournal of endocrinological investigation2025

Integrated analysis of gut microbiota, fecal and serum metabolites in type 2 diabetes mellitus with peripheral neuropathy.

Weisheng Xu, Qingqing Wang, Yongfei Yang, Shiyu Sun, Hui Qi, Jiantao He, Tong Jin, Ping Yao, Jiying Wang, Fuqing Lin

Abstract read
In one paragraph

Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weisheng Xu *Department of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. xuweisheng203@163.com.ORCID http://orcid.org/0000-0001-6649-6297
Qingqing Wang *Department of Anesthesiology, Shanghai Putuo People's Hospital, Tongji University School of Medicine, Shanghai, China.
Yongfei Yang *Department of Anesthesiology, Shanghai Stomatological Hospital, Fudan University, Shanghai, China.
Shiyu SunDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Hui QiDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Jiantao HeDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Tong JinDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Ping YaoDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
Jiying WangDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. 815888133@qq.com.
Fuqing LinDepartment of Pain Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China. fuqinglin@tongji.edu.cn.

Funding

the Youth Fund for Specialized Clinical Research of the Health Commission 20214Y0149
6 · The paper itself

Abstract

purposeDiabetic peripheral neuropathy (DPN) is one of the most common complications of type 2 diabetes mellitus (T2DM). In recent years, it has been reported that the progression of DPN is associated with altered gut microbiota and serum metabolites. However, the alterations of the gut microbiota and interaction with metabolites are not well understood in DPN patients. Therefore, we compared the gut microbiota and fecal and serum metabolic profiles of DPN and comprehensively analyzed the potential mechanisms of DPN.

methodsA total of 50 patients were divided into two groups: T2DM group without DPN (T2DM group) and T2DM group with DPN (DPN group). Fecal and serum samples of all patients were collected, and serum metabolites were determined by

resultsBacteria at the genus level in 8 and the species level in 13, and 28 fecal metabolites, and 5 serum metabolites were significantly altered in DPN patients. In particular, genus Faecalibacterium, species Collinsella_aerofaciens, fecal glycocholic acid and serum formate were significantly reduced in DPN, while genus Megamonas, fecal maleamic acid and serum uric acid (UA) were enriched. These changes are related to bile acid metabolism, amino acid metabolism, and mitochondrial dysfunction, as well as significantly correlated with VAS score, TCSS score and electromyography indicators.

conclusionThis study discovered the abnormal gut microbiota in DPN patients, with alterations in fecal and serum metabolism. It is speculated that the gut microbiota may lead to metabolic imbalance, accelerating the DPN progression. Multi-omics analysis was used to identify the possible mechanism of the gut microbiota-metabolism-mitochondrial axis in the progression of DPN, which may provide a potential therapeutic target for the diagnosis and treatment of DPN.

Indexed as

BiomarkersDiabetes Mellitus, Type 2Diabetic NeuropathiesFecesGastrointestinal MicrobiomeAgedFemaleHumansMaleMetabolomicsMiddle AgedPrognosisBiomarkersCorrelation analysisFecal metabolismGut microbiotaSerum metabolismType 2 diabetic peripheral neuropathy

Identifiers

PMID40627081
PMCPMC12518490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.